2018 IPO
Allogene Therapeutics Stock
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Sign up today and learn more about Allogene Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Allogene Therapeutics Stock
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment.
Funding History
April 2018 | $412M |
---|---|
September 2018 | $120M |
Management
Chief Executive Officer and Co-Founder
David Chang
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase